daNIS-2
12 Apr 2022
Trial Summary
A randomized, double-blind, phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nabpaclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC)
Acronym:
CNIS PANCREATIC
ACTRN/NCT /ethics:
NCT04935359
Scientific title:
Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) – daNIS-2
Sponsor / Cooperative group:
Novartis Pharmaceuticals
Trial & Patient Characteristics
| Cancer Type | Pancreas |
|---|---|
| Trial Type | Treatment |
| Phase | Phase III |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | Metastatic or Widespread |
| Anticipated Start Date | 2021-09-30 |
| Anticipated End Date | 2026-01-01 |
Participating Hospitals
| Hospital | Cancer Research SA |
|---|---|
| Clinical Trial Coordinator | Kelly Mead |
| admin@cancerresearchsa.com.au | |
| Phone | 08 8359 2565 |
| Principal Investigator | A/Prof Rohit Joshi |
| Recruitment Status | Recruiting |